ROCKVILLE, Md., Feb. 3, 2015 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific
therapies for serious infections and diseases, with a focus on
protecting the microbiome, announced today that Jeffrey Riley, CEO, is scheduled to present at
the BIO CEO & Investor Conference on Monday, February 9, 2015, at 1:30 p.m. (ET) at the Waldorf Astoria (Conrad
room) in New York.
A live webcast of Synthetic Biologics' presentation may be
accessed by logging onto the internet at
http://www.veracast.com/webcasts/bio/ceoinvestor2015/42118168151.cfm.
After the presentation, a replay will be archived and accessible
for 90 days at the same website.
Jeffrey Riley will also
participate on the "Trust Your Gut"—Therapeutic Opportunities
from the Microbiome panel at the 2015 BIO CEO & Investor
Conference on Tuesday, February 10,
2015, at 8:00 a.m. (ET) in the
Waldorf Astoria Jade room. This moderated panel will review
emerging data that the bacterial colonies of the digestive system
(the gut microbiome) influence far more non-digestive systems than
previously believed, while creating natural antibiotics and other
compounds that may be an underleveraged source for efficient drug
discovery.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage
biotechnology company developing pathogen-specific therapies for
serious infections and diseases, with a focus on protecting the
microbiome. The Company is developing an oral biologic to protect
the gastrointestinal (GI) microflora from the effects of
intravenous (IV) antibiotics for the prevention of C.
difficile infection, an oral statin treatment to reduce the
impact of methane producing organisms on constipation-predominant
irritable bowel syndrome (C-IBS) and a monoclonal antibody
combination for the treatment of Pertussis being developed in
collaboration with Intrexon Corporation (NYSE: XON). In addition,
the Company is developing a Phase 2 oral estriol drug for the
treatment of relapsing-remitting multiple sclerosis (MS) and
cognitive dysfunction in MS. For more information, please visit
Synthetic Biologics' website at www.syntheticbiologics.com.
Logo -
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-present-at-the-2015-bio-ceo--investor-conference-300029609.html
SOURCE Synthetic Biologics, Inc.